Clinical Trials on Primary Myelofibrosis (MF)

Total 59453 results

Ascentage Pharma Group Inc.

Withdrawn

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Myelofibrosis

United States
Hamad Medical Corporation

Unknown

18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia (PMF/ET-FLT)

Essential Thrombocythemia | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

Qatar
Incyte Corporation
Novartis

Completed

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Myelofibrosis

France, United Kingdom, China, United States, Netherlands, Germany, Italy, Austria
Mayo Clinic
National Cancer Institute (NCI)

Completed

Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Chronic Myeloproliferative Disorders | Secondary Myelofibrosis
Pfizer

Terminated

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

United States, Japan
M.D. Anderson Cancer Center
Cephalon

Completed

CEP-701 for PH-negative Myelofibrosis

Leukemia | Myelofibrosis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Incyte Corporation

Active, not recruiting

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
University Hospital, Angers

Recruiting

Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. (BioScoreSMP)

Essential Thrombocythemia | Myeloproliferative Disorder | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

France
Central Hospital, Nancy, France

Completed

Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France (SYMFASCT)

Myelofibrosis
M.D. Anderson Cancer Center
Helsinn Healthcare SA

Completed

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Myeloproliferative Diseases

United States
St. Petersburg State Pavlov Medical University

Completed

PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis

Primary Myelofibrosis | Myeloproliferative Disorders

Russian Federation
Fred Hutchinson Cancer Center

Recruiting

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Fred Hutchinson Cancer Center

Recruiting

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Ronald Hoffman
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Terminated

Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis

Myelofibrosis

United States
National Cancer Institute (NCI)

Completed

Thalidomide in Treating Patients With Myelofibrosis

Primary Myelofibrosis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders

United States, United Kingdom, France
M.D. Anderson Cancer Center
Incyte Corporation

Completed

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

Myeloproliferative Diseases

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis

Secondary Myelofibrosis

United States
Celgene

Completed

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

Myelofibrosis | Myeloid Metaplasia | Myelofibrosis With Myeloid Metaplasia

United States, Italy, United Kingdom, Austria, Spain
CTI BioPharma
SGS S.A.

Completed

PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects

Myelofibrosis

Moldova, Republic of, Germany, Romania
Celgene

Completed

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Primary Myelofibrosis | Anemia

United States, France, Italy, United Kingdom
Universitätsklinikum Hamburg-Eppendorf

Completed

Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients

Myelofibrosis

Germany
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

A New Blood Score for Myelofibrosis Staging (FIBROMOELLE)

Myeloproliferative Neoplasm
Sumitomo Pharma America, Inc.

Recruiting

A Study of Oral TP-3654 in Patients With Myelofibrosis

Myelofibrosis

United States, Japan, Australia
Massachusetts General Hospital
Incyte Corporation

Active, not recruiting

Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.

Myelofibrosis

United States
GlaxoSmithKline

No longer available

Managed Access Program for Momelotinib in Myelofibrosis

Primary Myelofibrosis | Myelofibrosis
Incyte Corporation

Completed

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

MPN (Myeloproliferative Neoplasms)

United States, Netherlands, Austria
Gruppo Italiano Trapianto di Midollo Osseo

Completed

Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis (GITMO-MF2010)

Myelofibrosis

Italy
Sanofi

Completed

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

Myelofibrosis

United States
Washington University School of Medicine
Rigel Pharmaceuticals

Terminated

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Myelofibrosis | Thrombocytopenia

United States
Geron Corporation

Completed

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis | Myeloid Malignancies

United States
University of Utah

Recruiting

Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis (ATIOM)

Myelofibrosis

United States
French Innovative Leukemia Organisation

Completed

JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis

Myelofibrosis

France
Novartis Pharmaceuticals

Completed

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Idiopathic Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia-Vera Myelofibrosis

United Kingdom, Ireland, Germany, Italy, France
Incyte Corporation

Completed

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

MPN (Myeloproliferative Neoplasms)

United States
University Hospital, Angers
Ligue contre le cancer, France

Recruiting

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) (CALRSUIVI)

Essential Thrombocythemia | Myeloproliferative Neoplasm | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

France
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Austria, Spain, Australia, Canada, Japan, United States, Korea, Republic of, Romania, Israel, Italy, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Colombia, Argentina, Chile and more
Karyopharm Therapeutics Inc

Not yet recruiting

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia (SENTRY-2)

Myelofibrosis | Moderate Thrombocytopenia
Universitätsklinikum Hamburg-Eppendorf
Novartis; Clinical Trial Center North (CTC North GmbH & Co. KG)

Active, not recruiting

Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability

Bone Marrow Fibrosis

Germany
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; Incyte Corporation

Recruiting

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Myelofibrosis Due to and Following Polycythemia Vera

United States
Novartis Pharmaceuticals
Incyte Corporation

Terminated

A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Myelofibrosis

Spain, United Kingdom, Australia, Israel, Germany, Italy, Singapore, Austria, France
Gemin X

Completed

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia

Myelofibrosis

United States, Canada
Northwestern University
National Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma Society

Withdrawn

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

United States
Sierra Oncology LLC - a GSK company

Completed

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Primary Myelofibrosis (PMF) | Post-polycythemia Vera (Post-PV) Myelofibrosis | Postessential Thrombocythemia (Post-ET) Myelofibrosis

United States, Canada
Disc Medicine, Inc

Recruiting

Study of DISC-0974 in Participants With Myelofibrosis and Anemia

Primary Myelofibrosis | Anemia | Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis | Myelofibrosis; Anemia | Myelofibrosis Due to and Following Polycythemia Vera

United States
Sanofi

Completed

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib (JAKARTA2)

Hematopoietic Neoplasm

United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom
Infinity Pharmaceuticals, Inc.

Completed

A Phase 2 Study With IPI-926 in Patients With Myelofibrosis

Primary Myelofibrosis | Fibrosis, Bone Marrow

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders

United States
Hamad Medical Corporation

Terminated

18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

Qatar

Clinical Trials on Primary Myelofibrosis (MF)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations